Research and Innovation Research and Innovation An Overview of European Commission Activities on Infectious Diseases Ole Olesen Unit Infectious Diseases.

Research and Innovation


An Overview of European Commission Activities on

Infectious Diseases

Ole OlesenUnit Infectious Diseases and Public Health

Directorate-General for Research and InnovationEuropean Commission

STOA – Aviesan Workshop, Bruxelles – 19 June 2012

PolicyPolicy Research and Innovation


The role of the European Commission - Research and innovation

Develop and implement the European research and innovation policy agreed by the European Parliament and European Council.

Funds research through multi-annual framework programmes for research (since 1984).

7th Framework Programme (2007-2013) has a total budget of 53 billion billion € - 4% of the total EU budget.

The European Commission manages about 5% of total public spending in R&D in the European Union.



Total funding: € 53 billion

The 7The 7thth EU Framework Programme (2007- EU Framework Programme (2007-

2013) 2013)

4

EU27

The power of collaboration



Main policy drivers:

Improving health of European citizens

Increasing competitiveness of European health-related industries

Global health issues, incl. emerging epidemics



Objectives for Infectious Diseases in FP7:to improve prevention, diagnostics and treatment of infectious diseases by supporting scientific collaboration between

•Countries•Sectors – public and private

•Area of research

Approximate annual average budget for infectious diseases in FP7: €100 million



Key priorities for infectious diseases in the Health Theme

• Emerging infectious diseases Influenza and other emerging diseases

(incl vector-borne diseases)

• Anti-microbial resistance

• Poverty-related diseases HIV/AIDS, Tuberculosis, malaria

• Neglected Infectious diseases



Distribution in FP7 – so far

Emerging infectious diseases (incl. influenza)Projects: 29 EU contribution: € 141 M

Antimicrobial resistanceProjects: 26 EU contribution: € 131 M

HIV/AIDS, malaria, tuberculosisProjects: 51 EU contribution: € 206 M

Neglected infectious diseases Projects: 15 EU contribution: € 65 M



FP7-funded projectson antimicrobial resistance

• Bacterial infections: 20 projects

• Viral infections: 7 projects

• Protozoan infections: 4 projects

• Fungal infections: 1 project

26 projects in the Health Theme: €131 Mio

“EU Research on Antimicrobial Resistance” presents a selection of these projects:

http://ec.europa.eu/research/health>>Infectious Diseases >>Anti-Microbial Drug Resistance



Co-operation between EU Member States: Joint programming on AMR

• Pulls together national research efforts, uses public resources better, and tackles key common challenges

• Initiative lead by Sweden

• 18 Countries BE, CH, CZ, DE, DK, ES, FI, FR, GR, IL, IT, NL, NO, PL, RO, SE,TK and UK involved

• Only 2 countries (DE and NL) have earmarked programmes for AMR research funding – the others fund AMR research as a result of bottom-up competition.

• Development of a common vision and strategic research agenda – expected this year

• Implementation of joint activities in 2013?



Emerging infectious diseases (including influenza)

29 projects with total EC funding of €141M

16 projects exclusively on human influenza €49M 3 projects on influenza and other emerging pathogens €36M 10 projects on emerging diseases excluding influenza €56M



Disease burden (DALY/year 1000s)

Global prevalence

Annual deaths

58 513 34 million 1.8 million

WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, GenevaUNAIDS World AIDS day report, 2011

Key goals in HIV/AIDS research: 18 projects, €84million

• Basic science 3 projects, €1.5M• Drug discovery 3 projects, €8.5M• Vaccines 5 projects,

€32.0M• Microbicides 1 projects,

€12.5M• Diagnostics 2 projects,

€2.0M• Clinical management/treatment 4 projects,

€24.0M• Overarching ERA-NET 1 project, €2.0M

HIV / AIDS



TuberculosisDisease burden (DALY/year 1000s)

Global prevalence

Annual deaths

34 217 13.9 million 1.464 million

Key goals in tuberculosis research: 15 projects, €66 million

• Basic science/host-pathogen interaction 7 projects, €14.5M

• Drug discovery 3 projects, €21.0M• Vaccines 2 projects,

€12.5M• Diagnostics 2 projects,

€6.0M• Clinical management/public health 1 project,

€12.0MWHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.



Disease burden (DALY/year 1000s)

Global prevalence

Annual deaths

33 976 million 889 000

Key goals in malaria research: 18 projects, €56million

• Basic science/host-pathogen interaction 4 projects, €20.3M

• Vector research 5 projects, €20.8M• Drug discovery 3 projects, €4.6M• Vaccines 5 projects,

€7.4M• Diagnostics 1 project,

€2.8M

Malaria

WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.



Neglected infectious diseases

Priority disease Disease burden (DALY/year 1000s)

Global prevalence

Annual deaths

Leishmaniasis 1974 12 million 47 000

Sleeping sickness 1673 <100 000 52 000

Chagas disease 430 8-9 million 11 000

Key goals in NID research: 15 projects, €65M

Protozoa (Leishmaniasis, Sleeping sickness, Chagas) Bacteria (Buruli Ulcer, Diarrhoeal diseases) Helminths (Schistosomiasis, Onchocerciasis, Filariasis)

• Basic immunology 5 projects, €13.1M• Vector control/public health 7 projects, €10.5M• Drug discovery 6 projects, €11.0M• Vaccines 7 projects, €25.7M• Diagnostics 3 projects, €4.7M

WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.Hotez et al. (2009) Lancet 373:1570-1575.



Collaborative projects improves the European Research Infrastructure

• Consist of 23 beneficiaries from 16 countries + more than 100 collaborating centres

• Access to data from over 250,000 HIV positive people

1616

• Coordinator: Prof. Kholoud Porter, MRC clinical trials unit, London, UK

• EU contribution: € 12 M

• Unique resource

von Bethlenfalvy

see word document for reformulation



European Developing Countries Clinical Trials Partnership (EDCTP)

• Public-Public Partnership: Joint initiative between 16 Member States and European Commission, established under art. 185

• Independent legal entity (EEIG)

• Coordination of European national programmes for clinical trials in Africa for HIV/AIDS, malaria, TB

• EC contribution of 200 mill Euro + MS contribution of 200 mill Euro

• Launched in 2004, to be renewed 2014 (EDCTP-2)

1717

200 M €

200 M €

von Bethlenfalvy




Innovative Medicines Initiative (IMI)

• Public-private partnership, initiative under Article 187

• Collaboration between EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA) as a Joint Technology Initiative under FP7

• Objective: to make drug discovery and development more efficient; to bring better medicines faster to patients; and to attract research investment to Europe

• Support / Funding of research activities following open Calls and independent review

1818

von Bethlenfalvy




Next steps…

• FP7

• Next call for proposals under Health (to be published in July 2012) contains new opportunities for building research infrastructures

• Large Topics (EU contribution up to 24 M Euro) on "Clinical management of patients in severe epidemics"

• Medium-sized topic (EU contribution up to 6 M Euro) on "Drug discovery platform for neglected parasitic diseases"

20 Research and

Innovation

Research and

Innovation

Horizon 2020The EU Framework

Programme for Research and Innovation

2014-2020

THE Future



Three priorities:1. Excellent science (≈ 30%)

2. Industrial leadership (≈ 30%)

3. Societal challenges (≈ 40%)

Commission has proposed €80 billion budget for 2014-2020

Legislative decision by MS and EP during 2012-2013

Horizon 2020 will start 1 January 2014



Among the Societal Challenges identified :

HEALTH, DEMOGRAPHIC CHANGE

AND WELL-BEING

• How to provide better health, while • maintaining an economically sustainable healthcare system ?

• More health for the money !



HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING

Main Specific Research Lines Considered• Effective health promotion and disease

prevention Understanding the determinants of health, improving

health promotion and disease prevention Developing effective screening programmes and

improving the assessment of disease susceptibility Improving surveillance and preparedness of infectious

diseases Developing better preventive vaccines and evidence-

based vaccination schemes




Main Specific Research Lines Considered• Manage, treat and cure diseases and disabilities

Understanding disease Improving diagnosis Using in-silico medicine for improving disease

management and prediction Treating disease Transferring knowledge to clinical practice Individual empowerments for self-management of health

and integrated care




Main Specific Research Lines Considered• Translating research into better healthcare

Better use of health data Improving scientific tools and methods to support policy

making and regulatory needs Active ageing, independent and assisted living Optimising the efficiency and effectiveness of healthcare

systems and reducing inequalities



Thank you

European CommissionDG Research and InnovationInfectious Diseases and Public Health

Research and Innovation Research and Innovation An Overview of European Commission Activities on Infectious Diseases Ole Olesen Unit Infectious Diseases.

Documents

innovation research

policy research

european research

tuberculosis research

malaria research

innovation policy

hivaids research

amr research